ROCKAWAY, N.J. , Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress
electroCore Granted Two New U.S. Patents ROCKAWAY, N.J. , Dec. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark
ROCKAWAY, N.J. , Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or
ROCKAWAY, N.J. , Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “ Accessing the Power of Vagus Nerve
Record third quarter 2023 net sales of $4.5 million , an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million Company to host a conference call and webcast today, November 8, 2023 at 4:30 PM EST ROCKAWAY, N.J.
ROCKAWAY, N.J. , Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger , is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services
Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia ROCKAWAY, N.J. , Oct. 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today
Extension maintains listing through March 17, 2026 ROCKAWAY, N.J. , Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom’s National
ROCKAWAY, N.J. , Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a treatment protocol for nVNS. U.S. Patent No.
“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH) “NOVIS” Clinical Trial (n=150) of nVNS for the acute treatment of Ischemic Stroke will complete recruitment in 2023 ROCKAWAY, N.J. , Oct.